Sarepta Therapeutics, Inc. (SRPT)

NASDAQ: SRPT · Real-Time Price · USD
36.52
-0.20 (-0.54%)
At close: May 8, 2025, 4:00 PM
36.85
+0.33 (0.90%)
After-hours: May 8, 2025, 5:23 PM EDT
-0.54%
Market Cap 3.59B
Revenue (ttm) 2.23B
Net Income (ttm) -248.39M
Shares Out 98.28M
EPS (ttm) -2.59
PE Ratio n/a
Forward PE 10.78
Dividend n/a
Ex-Dividend Date n/a
Volume 9,244,102
Open 37.20
Previous Close 36.72
Day's Range 35.48 - 38.00
52-Week Range 35.46 - 173.25
Beta 0.84
Analysts Buy
Price Target 131.09 (+258.95%)
Earnings Date May 6, 2025

About SRPT

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat Duchenne muscular dystrophy (Duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of Duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Jun 3, 1997
Employees 1,372
Stock Exchange NASDAQ
Ticker Symbol SRPT
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 23 analysts, the average rating for SRPT stock is "Buy." The 12-month stock price forecast is $131.09, which is an increase of 258.95% from the latest price.

Price Target
$131.09
(258.95% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Sarepta Therapeutics to Present at the BofA Securities Health Care Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will participate in a fi...

9 hours ago - Business Wire

Sarepta: ELEVIDYS DMD Treatment Setback Brings Downgrade To Hold Rating

Sarepta Therapeutics, Inc.'s gene therapy SRP-9003 for LGMD 2E/R4 subtype progresses, with potential BLA submission in H2 2025, possibly boosting shareholder value. SRPT rating changed from "Strong Bu...

1 day ago - Seeking Alpha

Sarepta Therapeutics Stock Sinks On Gloomy Forecast, Analysts Expect Demand To Pick Up

Sarepta Therapeutics Inc. SRPT reported on Tuesday that the first-quarter 2025 loss of $3.42 per share was missing the analyst consensus estimate of losses of 95 cents.

1 day ago - Benzinga

Sarepta Therapeutics: Lowered Elevidys Guidance Warrant Ratings Downgrade

Sarepta Therapeutics, Inc.'s stock is downgraded to Hold due to underperformance, safety concerns with ELEVIDYS, and increased expenses, despite strong long-term fundamentals. Q1 2025 results show mix...

1 day ago - Seeking Alpha

New vaccine chief rocks pharmaceutical stocks

CNBC's Angelica Peebles joins 'Squawk on the Street' to discuss how the biotech and pharma industry is reacting to a new FDA chief of vaccines appointed by President Trump.

1 day ago - CNBC Television

Sarepta Therapeutics Analysts Slash Their Forecasts After Q1 Results

Sarepta Therapeutics, Inc. SRPT posted a loss for the first quarter on Tuesday.

1 day ago - Benzinga

Sarepta Therapeutics, Mercury Systems, Arista Networks And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session

U.S. stock futures were higher this morning, with the Dow futures gaining over 300 points on Wednesday.

Other symbols: ANETMRCY
1 day ago - Benzinga

Sarepta Therapeutics, Inc. (SRPT) Q1 2025 Earnings Call Transcript

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Q1 2025 Earnings Conference Call May 6, 2025 4:30 PM ET Company Participants Mary Jenkins - Associate Director, IR Doug Ingram - President and CEO Dallan Murr...

2 days ago - Seeking Alpha

Sarepta Therapeutics Announces First Quarter 2025 Financial Results and Recent Corporate Developments

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today reported financial results for the first quarter 2025. “I...

2 days ago - Business Wire

SRPT Investors Have Opportunity to Join Sarepta Therapeutics, Inc. Fraud Investigation with the Schall Law Firm

LOS ANGELES , May 5, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Sarepta Therapeutics, ...

3 days ago - PRNewsWire

Sarepta Therapeutics to Announce First Quarter 2025 Financial Results

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report first quarter 2025 financial results after the Nasd...

16 days ago - Business Wire

Sarepta Therapeutics Announces Pipeline Progress for Multiple Limb-Girdle Muscular Dystrophy Programs

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today shared updates from its clinical programs focused on limb...

23 days ago - Business Wire

Sarepta halts three studies testing gene therapy for muscle disorder

Sarepta Therapeutics said on Friday it would temporarily halt three trials testing its gene therapy Elevidys.

4 weeks ago - Reuters

Sarepta Therapeutics Provides Update on ELEVIDYS

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, shared the following update related to ELEVIDYS (delandistrogen...

4 weeks ago - Business Wire

Sarepta/Roche Suspend Elevidys Gene Therapy Trials In Europe After Patient Death

In March, Sarepta Therapeutics, Inc. SRPT shared an update on Elevidys (delandistrogene moxeparvovec-rokl), the only approved gene therapy in patients with Duchenne muscular dystrophy.

5 weeks ago - Benzinga

Bronstein, Gewirtz & Grossman, LLC Is Investigating Sarepta Therapeutics, Inc. (SRPT) And Encourages Shareholders to Connect

NEW YORK, NY / ACCESS Newswire / April 3, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Sarepta Therapeutics, Inc. ("Sarepta" or "the Company")...

5 weeks ago - Accesswire

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Sarepta Therapeutics, Inc. (SRPT) And Encourages Shareholders to Reach Out

NEW YORK, NY / ACCESS Newswire / April 2, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Sarepta Therapeutics, Inc. ("Sarepta" or "the Company")...

5 weeks ago - Accesswire

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Sarepta Therapeutics, Inc. (SRPT) and Encourages Shareholders to Learn More About the Investigation

NEW YORK, NY / ACCESS Newswire / April 1, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Sarepta Therapeutics, Inc. ("Sarepta" or "the Company")...

5 weeks ago - Accesswire

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on March 31, 2025 that were previously ap...

5 weeks ago - Business Wire

Drug stocks sink as FDA's top vaccine official is ousted in Trump overhaul

Shares of U.S. drugmakers fell on Monday after reports that the Food and Drug Administration's top vaccine official was forced to resign, the most high-profile exit at the regulator as the Trump admin...

Other symbols: BNTXNVAXSLDBTSHAXBI
5 weeks ago - New York Post

Sarepta Therapeutics, Inc. (SRPT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation

NEW YORK, NY / ACCESS Newswire / March 31, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Sarepta Therapeutics, Inc. ("Sarepta" or "the Company"...

5 weeks ago - Accesswire

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Sarepta Therapeutics, Inc. (SRPT) and Encourages Investors to Learn More About the Investigation

NEW YORK, NY / ACCESS Newswire / March 30, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Sarepta Therapeutics, Inc. ("Sarepta" or "the Company"...

5 weeks ago - Accesswire

Sarepta Therapeutics, Inc. (SRPT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

NEW YORK, NY / ACCESS Newswire / March 28, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Sarepta Therapeutics, Inc. ("Sarepta" or "the Company"...

5 weeks ago - Accesswire

Bronstein, Gewirtz & Grossman, LLC Is Investigating Sarepta Therapeutics, Inc. (SRPT) And Encourages Investors to Connect

NEW YORK, NY / ACCESS Newswire / March 27, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Sarepta Therapeutics, Inc. ("Sarepta" or "the Company"...

6 weeks ago - Accesswire

Bronstein, Gewirtz & Grossman, LLC Encourages Sarepta Therapeutics, Inc. (SRPT) Stockholders to Inquire about Securities Investigation

NEW YORK, NY / ACCESS Newswire / March 26, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Sarepta Therapeutics, Inc. ("Sarepta" or "the Company"...

6 weeks ago - Accesswire